Rosalinda Syto
Schering-Plough
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rosalinda Syto.
Journal of Biomolecular Screening | 2004
Zhuomei Lu; Zhizhang Yin; Linda James; Rosalinda Syto; Jill M. Stafford; Sandra Koseoglu; Todd W. Mayhood; Joseph E. Myers; William T. Windsor; Paul Kirschmeier; Ahmed A. Samatar; Bruce A. Malcolm; Tammy C. Turek-Etienne; C. Chandra Kumar
Most of the protein kinase inhibitors being developed are directed toward the adenosine triphosphate (ATP) binding site that is highly conserved in many kinases. A major issue with these inhibitors is the specificity for a given kinase. Structure determination of several kinases has shown that protein kinases adopt distinct conformations in their inactive state, in contrast to their strikingly similar conformations in their active states. Hence, alternative assay formats that can identify compounds targeting the inactive form of a protein kinase are desirable. The authors describe the development and optimization of an Immobilized Metal Assay for Phosphochemicals (IMAP™)-based couple™d assay using PDK1 and inactive Akt-2 enzymes. PDK1 phosphorylates Akt-2 at Thr 309 in the catalytic domain, leading to enzymatic activation. Activation of Akt by PDK1 is measured by quantitating the phosphorylation of Akt-specific substrate peptide using the IMAP assay format. This IMAP-coupled assay has been formatted in a 384-well microplate format with a Z′ of 0.73 suitable for high-throughput screening. This assay was evaluated by screening the biologically active sample set LOPAC™ and validated with the protein kinase C inhibitor staurosporine. The IC50 value generated was comparable to the value obtained by the radioactive 33P-γ-ATP flashplate transfer assay. This coupled assay has the potential to identify compounds that target the inactive form of Akt and prevent its activation by PDK1, in addition to finding inhibitors of PDK1 and activated Akt enzymes.
Proteins | 1996
William T. Windsor; Leigh J Walter; Rosalinda Syto; James Fossetta; William J. Cook; Tattanahalli L. Nagabhushan; Mark R. Walter
X‐ray diffraction quality crystals have been obtained from a complex between interferon γ and the extracellular domain of its high‐affinity cell surface receptor. The crystals were obtained from interferon γ/interferon γ receptor complexes purified by size exclusion chromatography. Diffraction quality crystals required analyzing these complex samples by isoelectric focusing gels to select purified complex fractions devoid of unbound interferon γ. These studies used interferon γ receptor engineered with an eight amino acid N‐terminal deletion to eliminate heterogeneity generated due to proteolytic cleavage. In addition, the receptor was expressed in an E. coli secretion cell line which eliminated the need to refold the protein. Hexagonal crystals were grown from 1.6 M ammonium phosphate solutions and belong to a spacegroup of P6522 with unit cell dimensions a = 145.9 Å and c = 180.3 Å. These crystals diffract to at least 2.9 Å resolution when exposed to synchrotron radiation. SDS PAGE analysis of the crystals demonstrated that both interferon γ and the receptor were present. Analysis of the x‐ray diffraction data revealed that the crystals contain complexes with a stoichiometry of 2:1 receptor: ligand within the crystallographic asymmetric unit and consist of approximately 55% solvent.
Biochimica et Biophysica Acta | 1989
Lata Ramanathan; Hung V. Le; James E. Labdon; Carol A. Mays-Ichinco; Rosalinda Syto; Naoko Arai; Tattanahalli L. Nagabhushan; Paul P. Trotta
Recombinant murine interleukin-4 (muIL-4) expressed in COS-7 monkey kidney cells was purified to homogeneity by sequential CM-Sepharose, Sephadex G-100 chromatography and mono-S FPLC to a specific activity of 6.10(7) units per mg of protein based on an in vitro HT-2 cell proliferation assay. Two electrophoretic variants, designated a and b, which migrated on SDS-PAGE as a closely spaced doublet with Mr 19,000, were present in the final product. Gas phase sequencing of the purified protein revealed the presence of an N-terminus corresponding to the mature protein predicted from the cDNA sequence and sequencing of a cyanogen bromide digest confirmed 75 of the 120 predicted amino acids. Elution behavior on gel filtration corresponded to that of a monomer of Mr 19,000. Since there are three potential sites of N-glycosylation predicted by the cDNA sequence, the contribution of glycosylation to the observed heterogeneity was examined by treatment with endoglycosidases. Variant b was digested by either endo-beta-N-acetylglucosaminidase H (endo H) or endo-beta-N-acetylglucosaminidase F (endo F) to protein of Mr 15,000 on SDS-PAGE but was unaffected by treatment with endo-beta-N-acetylglucosaminidase D (endo D), thus indicating the presence of high mannose type of N-glycan. In contrast, variant a was resistant to endo H, F and D. Complete conversion of a mixture of variants a and b to a single protein of Mr 15,000 on SDS-PAGE was obtained only after treatment with N-glycanase. Both variants were resistant to neuraminidase and O-glycanase treatment. These data show that the microheterogeneity observed in purified muIL-4 preparations is due to differences in the nature of the N-linked oligosaccharides. The availability of purified recombinant muIL-4 and a methodology for both total and selective deglycosylation provides a basis for the initiation of structure-function studies of this novel T-cell lymphokine.
Biochimica et Biophysica Acta | 1988
Hung V. Le; Rosalinda Syto; Jerome Schwartz; Tattanahalli L. Nagabhushan; Paul P. Trotta
The human interferon (huIFN) delta-4 alpha 2(5-62)/alpha 1(64-166) is a genetically engineered hybrid that consists of residues 5-62 of huIFN alpha 2 and residues 64-166 of huIFN alpha 1. This variant contains four cysteine residues at positions 29, 86, 99 and 139, but does not contain the cysteine at position 1 that is characteristic of naturally occurring huIFN alpha subtypes. This novel recombinant hybrid was purified from Escherichia coli to greater than 95% homogeneity. The purification was based on ethanol extraction of a trichloroacetic acid precipitate and Matrex Gel Blue A chromatography followed by either a selective precipitation or DEAE-Sepharose chromatography. The purified protein that was treated with 2-mercaptoethanol exhibited two closely migrating bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with apparent molecular weight values of 17,800 and 17,100, both of which exhibited antiviral activity. Electrophoresis performed without prior reduction with 2-mercaptoethanol indicated only a minor extent of intermolecular disulfide bonding. The purified protein exhibited a high specific antiviral activity of 7 x 10(7) units/mg when assayed on human fibroblast cells and, in distinction to the parental huIFN alpha 2, it also demonstrated antiviral activity on human fibroblast cells and, in distinction to the parental huIFN alpha 2, it also demonstrated antiviral activity on murine L929 cells. The level of antiproliferative activity of huIFN delta-4 alpha 2(5-62)/alpha 1(64-166) on various cell lines of different histological origin appeared to be more comparable to that of huIFN alpha 1 than huIFN alpha 2. The data suggest that huIFN delta-4 alpha 2(5-62)/alpha 1(64-166) hybrid may be a useful tool for understanding huIFN structure-function relations.
Journal of Biological Chemistry | 1997
Fang L. Zhang; Paul Kirschmeier; Donna Carr; Linda James; Richard W. Bond; Lynn Wang; Robert Patton; William T. Windsor; Rosalinda Syto; Rumin Zhang; W. Robert Bishop
Biochemistry | 1998
Corey Strickland; William T. Windsor; Rosalinda Syto; Lynn Wang; Richard W. Bond; Zhen Wu; Jeffrey Schwartz; Hung V. Le; Lorena S. Beese; Patricia C. Weber
Biochemistry | 1993
William T. Windsor; Rosalinda Syto; Anthony Tsarbopoulos; Rumin Zhang; James Durkin; Samuel Baldwin; Smita Paliwal; Philip W. Mui; Birendra N. Pramanik
Journal of Biological Chemistry | 1988
Hung V. Le; Lata Ramanathan; James E. Labdon; C. A. Mays-Ichinco; Rosalinda Syto; N. Arai; P. Hoy; Y. Takebe; Tattanahalli L. Nagabhushan; Paul P. Trotta
Biochemistry | 1998
Rosalinda Syto; Nicholas J. Murgolo; Emory H. Braswell; Philip W. Mui; Eric Huang; William T. Windsor
Analytical Biochemistry | 2004
Rumin Zhang; Todd W. Mayhood; Philip Lipari; Yaolin Wang; James Durkin; Rosalinda Syto; Jennifer J. Gesell; Charles McNemar; William T. Windsor